Presented by Interactive Offers: Ebola is Exploding in the DRC and NanoViricides (NNVC) is About to Put its Broad-Spectrum Antiviral NV-387 to the Human Test →

Beating the number isn't enough this morning: the biggest premarket winners cleared the bar by a wide margin or raised it themselves, led by a consulting heavyweight that topped its own forecast and a power tech name lifting guidance on royalty income.

A shot-down deal rumor and a record launch contract round out the gainers. But a clean beat from one closely watched chipmaker still isn't finding buyers, a reminder of how high the bar is running.

NanoViricides (NNVC) is Moving NV-387 into a Critical Phase II Ebola Trial Just as a Fast-Growing Outbreak Creates Urgent Demand for New Antiviral Treatments!

NanoViricides (NYSE American: NNVC) is entering a potentially important chapter as its lead antiviral candidate, NV-387, prepares to move into a Phase II clinical trial for Ebola in the Democratic Republic of Congo. 

With the current Bundibugyo ebolavirus outbreak continuing to expand and carrying a crude fatality rate above 48%, the need for new treatment options is significant. What makes the development particularly noteworthy is that NV-387 is being evaluated as an oral therapy, potentially offering a more practical method of administration than treatments requiring infusion. 

The upcoming trial will begin putting NV-387 to the ultimate test: whether the drug's preclinical promise can translate into meaningful results in human patients.

But Ebola is only one part of the NNVC story. NanoViricides is also advancing NV-387 as a potential treatment for measles, with the candidate having received FDA Orphan Drug and Rare Pediatric Disease designations for that indication. 

With measles cases continuing to rise in the U.S. and internationally, the company is pursuing another potential clinical pathway for the same broad-spectrum antiviral platform. 

There is no guarantee NV-387 will succeed in clinical development, but with an Ebola Phase II trial approaching and the measles program advancing behind it, NNVC now has multiple developments for biotech investors to watch!

Keep NNVC on your radar as the company prepares to generate potentially important human clinical data from NV-387. Timing is critical!

Accenture (ACN): +18%

The consulting giant is soaring after fiscal fourth-quarter revenue beat Wall Street's estimate and cleared the top of the company's own guidance range, with earnings also coming in ahead of expectations. When a company beats the high end of its own forecast, it signals demand is running ahead of what even management expected.

Vicor (VICR): +12%

Vicor raised its third-quarter revenue growth outlook to more than 30%, up from at least 20%, citing higher royalties from its first non-exclusive Vertical Power Delivery license. A guidance hike driven by licensing income is a different kind of growth than selling more parts, and the market is reading it as a sign the technology itself is gaining traction.

Nu Holdings (NU): +5%

The Brazilian digital bank is rallying after denying it's pursuing a transaction with UK digital bank Monzo, responding directly to media speculation that it was an acquirer. The reaction suggests investors were more nervous about a big cross-border deal than excited by it, and the denial takes that overhang off the table.

Rocket Lab (RKLB): +4%

Rocket Lab signed a multiyear agreement with Synspective for 20 new Electron missions, which the company calls the largest commercial launch contract in Electron's history. A 20-mission commitment gives the launch business visibility years out, the kind of backlog that shifts the story from mission-by-mission to recurring.

Micron (MU): -1%

Micron beat on both earnings and revenue in its fiscal fourth quarter, yet the stock is slipping while other semiconductor names, including memory and chip ETFs, trade higher. When a beat this clean can't lift the stock, it suggests expectations were already running very high going in.

NanoViricides (NYSE American: NNVC) is approaching a potentially major milestone as its lead antiviral candidate, NV-387, prepares to enter a Phase II clinical trial as a treatment for Ebola in the Democratic Republic of Congo. 

The timing puts the company directly in the middle of a significant medical need, with the current Bundibugyo ebolavirus outbreak continuing to expand and carrying a reported crude fatality rate above 48%. 

Unlike therapies requiring infusion, NV-387 is being evaluated as an oral treatment, which could potentially offer practical advantages in resource-limited outbreak settings if clinical testing ultimately demonstrates that it is safe and effective. 

Now, NNVC is moving from preclinical evidence into human testing, giving investors an important clinical catalyst to watch.

And Ebola isn't the only reason NNVC is getting attention. NanoViricides is also advancing NV-387 toward potential clinical development as a treatment for measles, where the company says cases continue to rise in the U.S. and around the world. 

NV-387 has received FDA Orphan Drug and Rare Pediatric Disease designations for measles, creating additional regulatory significance for the program, including potential Priority Review Voucher eligibility if the applicable requirements are ultimately met. 

With NV-387 being explored against multiple viral diseases, the upcoming Ebola trial could provide an important opportunity to see whether the company's broad-spectrum antiviral technology can translate into meaningful human clinical results. 

Keep NNVC firmly on your radar as the first Ebola patients prepare to receive NV-387 and the company enters this next stage of development!

Sellas Life Sciences (SLS)

StockTwits chatter around Sellas increased in 24 hours as sentiment climbed out of bearish territory. Traders are circling two threads: the Phase 3 Regal trial of its leukemia vaccine candidate sits at 78 of the 80 events needed to trigger final analysis, and some users are reading recently revised executive change-of-control terms as a hint that a buyout could be in play.

The buyout talk is pure speculation, but the stock is already up roughly 180% year-to-date, with initial Phase 2 data on a second leukemia drug expected in Q4. If the Regal trial crosses its threshold soon, this could be the stretch where that run either gets validated or gets tested.

✌️That’s it for today.